Why Merck’s MSD is paying up to $600m for Evaxion’s undisclosed vaccine candidate EVX-B3

Why did MSD license Evaxion’s AI vaccine candidate with $7.5 million upfront and nearly $600 million in milestones?

Merck & Co., Inc. (NYSE: MRK), through its international arm MSD, has moved decisively in the vaccine space by licensing Evaxion Biotech A/S’s (NASDAQ: EVAX) preclinical vaccine candidate EVX-B3. The deal begins with an upfront cash payment of $7.5 million, but the true scale lies in the structure: Evaxion is eligible for up to $592 million in additional development, regulatory, and commercial milestone payments, along with royalties on net sales if the vaccine reaches the market. MSD will assume full responsibility for development costs, giving Evaxion both financial relief and future upside potential.

EVX-B3 is still at the preclinical stage, which normally makes such deals speculative. What differentiates this candidate is its origin. It was discovered through Evaxion’s proprietary AI-Immunology platform, designed to model immune responses and predict novel vaccine targets that would not necessarily emerge from traditional discovery methods. By exercising its option on this candidate, MSD is signaling confidence in both the target and the underlying AI-driven discovery approach.

What makes EVX-B3 such a mystery and why does its undisclosed target matter for the industry?

The most intriguing aspect of the announcement is that Evaxion and MSD have not revealed the exact pathogen EVX-B3 is designed to fight. Evaxion has only said it is aimed at a “serious pathogen” for which there is no approved vaccine today. This secrecy reflects the competitive dynamics of the sector. If the candidate addresses a global unmet need such as antimicrobial-resistant bacteria or emerging viral threats, it could unlock a lucrative market.

However, withholding the target also adds uncertainty for investors. Analysts and sector watchers can only speculate about the potential market size, competitive positioning, and regulatory pathway. In biotech, transparency is often a catalyst for valuation growth, so future disclosures about EVX-B3 will be critical in shaping both scientific and market sentiment.

How does this deal fit into the historical context of AI-discovered vaccines and biopharma partnerships?

AI and machine learning have increasingly influenced drug discovery, particularly in oncology and small molecules. But the application of AI to vaccine discovery has lagged behind until recent years. Evaxion, founded in Denmark, has been among the first to apply systematic computational models to immunology. Its AI-Immunology platform aims to predict epitopes—antigen components that can generate immune responses—with greater precision.

Historically, vaccines have been developed through empirical testing and pathogen observation. The mRNA revolution of COVID-19 highlighted the power of platforms to accelerate design and delivery. AI represents the next leap. If EVX-B3 advances successfully, it will be one of the first clear validations that AI-designed vaccines can transition from concept to clinic. For MSD, which has long maintained leadership in vaccines with products like Gardasil and Vaxneuvance, partnering on an AI-born vaccine also ensures it remains ahead in an evolving competitive landscape where Pfizer, Moderna, and GSK are all expanding discovery methods.

What does this mean for Evaxion’s financial runway and balance sheet strength?

For Evaxion, the $7.5 million upfront payment is more than symbolic. Prior to this agreement, the company’s balance sheet reflected cash of about $14.7 million and debt of $11.3 million, leaving it with a modest net cash position. Its revenue in the last twelve months was just over $3 million, with a net loss close to $12 million. The infusion of non-dilutive cash from MSD extends its operating runway into the first half of 2027.

This is vital for a company that has faced persistent share price declines. Over the past 52 weeks, Evaxion stock fell by more than 70 percent, reflecting investor concerns about cash burn and execution risk. Partnerships like this one allow Evaxion to fund its operations without resorting to dilutive equity raises. The fact that MSD has taken on the development costs of EVX-B3 also reduces downside exposure for Evaxion while leaving its potential upside intact.

How did Evaxion’s stock react to the MSD licensing announcement and what is investor sentiment now?

The immediate market reaction was enthusiastic. Evaxion’s stock surged more than 25 percent on the day the deal was announced. Analysts pointed to the agreement as strong external validation of the company’s technology platform. With an average 12-month price target of around $11 compared to current levels near $4, some see significant upside if the partnership yields results.

Institutional data, however, paints a mixed picture. Only about 11 percent of shares are held by institutional investors. Some institutions have trimmed positions over the past two years, while others have added, suggesting cautious engagement. The low level of institutional ownership and high volatility mean Evaxion remains largely a retail-driven stock, prone to sharp swings on news flow.

Investor sentiment remains speculative. For bulls, the MSD deal proves that a major pharma player believes in Evaxion’s AI-immunology platform. For bears, the absence of clarity around the pathogen target and the risks inherent in preclinical assets are reasons for caution.

What is the status of Evaxion’s other AI vaccine candidate EVX-B2 and how does MSD’s option shape future expectations?

The deal with MSD also includes an option on EVX-B2, Evaxion’s gonorrhea vaccine candidate. That option period has been extended, with MSD expected to decide in the first half of 2026. Gonorrhea represents a significant unmet need in infectious disease, particularly with rising antibiotic resistance. If MSD exercises this option, it would further validate Evaxion’s approach and could transform the firm into a recurring partner for big pharma in infectious disease discovery.

The timing of the decision may also hinge on early data from EVX-B3. If EVX-B3 progresses smoothly into clinical development, confidence in the platform will grow, making it more likely MSD commits to EVX-B2 as well.

Why does the milestone structure of this deal protect MSD while still rewarding Evaxion?

Biotech licensing agreements often involve a combination of upfront payments, milestone payments, and royalties. This structure protects the larger company from overcommitting capital too early, while allowing the smaller firm to capture upside if programs succeed. MSD’s $7.5 million upfront commitment is relatively modest, but the nearly $600 million in potential milestones represents confidence in the upside if EVX-B3 passes key checkpoints.

For Evaxion, the milestone payments create a path to sustainable financing without equity dilution. If even a portion of the milestones are achieved, it could dramatically strengthen its cash position and accelerate its broader pipeline.

What are the broader industry implications of MSD’s nearly $600 million wager on AI-designed vaccines?

This partnership signals that artificial intelligence has moved from hype to strategic integration in big pharma’s vaccine strategies. Companies like Pfizer and Moderna have already applied computational models to optimize mRNA sequences, but Evaxion’s focus on epitope prediction represents a different approach.

If successful, AI-immunology could accelerate timelines, lower R&D costs, and open up vaccine opportunities against pathogens that have resisted conventional approaches. It could also shift dealmaking dynamics, with big pharma more willing to partner earlier in the discovery process. For investors, the MSD-Evaxion deal could be a bellwether for more AI-driven licensing agreements across biotech in the coming years.

What should investors and industry watchers look for next in Evaxion’s journey with MSD?

Several key milestones will shape the future of this deal and investor perception. The most important is the disclosure of EVX-B3’s pathogenic target, which will define the market opportunity and competitive context. Beyond that, Evaxion must advance EVX-B3 into Investigational New Drug (IND)-enabling studies, which test safety and immunogenicity before human trials can begin.

MSD’s decision on EVX-B2 in 2026 will also be pivotal. A positive decision would signal strong validation of Evaxion’s AI-platform, while a negative outcome could raise doubts about its broader applicability.

For investors, the path forward will be volatile but full of potential. Biotech milestones often trigger sharp price movements, and Evaxion’s small float and retail-heavy ownership base magnify those swings. Analysts suggest that while speculative, the stock may be positioned as a high-risk, high-reward play in the AI-biotech intersection.

In many ways, the MSD-Evaxion deal is about more than a single vaccine. It represents the growing willingness of established pharmaceutical giants to test the promise of AI-based discovery platforms. For Evaxion, it provides crucial validation, cash runway extension, and the potential for transformative upside. For MSD, it offers a foothold in the next wave of vaccine innovation. For the broader industry, it is a signal that the convergence of AI and immunology is no longer theoretical but is shaping billion-dollar strategies.